Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220473 · ClinicalTrials.gov registry record · Phase 2
Tirzepatide to Slow Biological Aging
A Phase 2 study, sponsored by The University of Texas Medical Branch, Galveston.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07220473 is a Phase 2 study that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 90 participants.
The verdict
NCT07220473, a Phase 2 study, is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg subcutaneously (SC) weekly or no drug for 24 weeks, followed by 12 weeks off the drug. Since tirzepatide is already recognized as a highly effective weight-loss agent in this population, the primary focus will not be on measuring weight loss. Instead, the study will document the effects of tirzepatide on markers of aging, physical function, and overall health.
Interventions
- DRUG Zepbound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-02-27 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220473
The ClinicalTrials.gov registry entry for NCT07220473 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zepbound is the first listed.
NCT07220473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07220473 about?
NCT07220473 is a clinical study titled "Tirzepatide to Slow Biological Aging". This pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg subcutaneously (SC) w...
What is the current status of trial NCT07220473?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-02-27. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07220473?
The interventions under investigation include: Zepbound (DRUG).
Who is sponsoring clinical trial NCT07220473?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.